Bedrijf laden
Just reported
Q3 2026 results
From Bristol Myers Squibb's results release of 29 oktober 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 13,07B
+6,9% y/y
+0,7% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ 1,05
-2,8% y/y
-35% q/qGuided
—
No guide given
Company outlook
Full year 2026
- RevenueUS$ 49B – US$ 50BRaised +5,9%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Bristol Myers Squibb is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And CompanyUS$ 1,36TA+
JNJJohnson & JohnsonUS$ 688,6BA+
MRKMerck & Co., Inc.US$ 364,3BA
NVSNovartis AGUS$ 306,3BA
AMGNAmgen Inc.US$ 251,9BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 okt 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 okt 2026CAGraded C, now A
Hoe het geld verdient
- Prescription medicines, plus royalties and alliance-related revenue100%
De omzetaandelen zijn schattingen voor FY2025, geen cijfers uit een ingediend rapport.
Concurreert met
Wat het verkoopt6
Opdivo
An immune-based cancer medicine used for several cancers, including lung cancer, melanoma and some blood cancers.
Eliquis
A pill that helps prevent stroke in people with a type of irregular heartbeat and treats blood clots in the legs or lungs.
Revlimid
A pill used to treat multiple myeloma, a cancer of plasma cells, as well as certain lymphomas and bone-marrow disorders.
Nog 3 tonen
Reblozyl
An injection that treats anemia, a shortage of healthy red blood cells, in people with certain blood disorders.
Breyanzi
A treatment made from a patient's own immune cells, which are changed and returned to the patient to treat certain blood cancers.
Camzyos
A pill for adults with obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle makes it harder for blood to leave the heart.
Wie het koopt5
- Wholesalers and distributors that buy medicines for onward sale to pharmacies, hospitals and other care providers.
- Specialty pharmacies that dispense certain medicines, including products subject to restricted distribution programs.
- Retail pharmacies, hospitals and clinics that purchase or dispense medicines.
Nog 2 tonen
- Government agencies and public health programs that buy medicines or cover their cost.
- Patients in the United States, including cash-paying patients using direct-to-patient access for certain products.
Waar het op steunt, en wat het kan breken
Waar het bedrijf van afhangt
- 1Patent rights and regulatory approvals protect many branded medicines from competing copies; generic competition can reduce sales when that protection ends.
- 2Access to insurance coverage and placement on health-plan medicine lists affect whether patients can obtain products and what the company receives for them.
- 3U.S. sales rely on a small group of wholesalers: the three largest represented about 90% of U.S. product gross sales (six months ended June 30, 2026, high).
- 4The company relies on outside suppliers for ingredients or drug substances for products including Eliquis, Opdivo, Yervoy, Pomalyst, Sprycel, Camzyos and Cobenfy.
- 5Some medicines are developed or sold with partners, which can bring shared costs or royalties and affect the company's rights to sell a product.
Wat er mis kan gaan
- 1Generic competition is already reducing sales of products including Revlimid, Pomalyst, Sprycel and Abraxane. Eliquis also faces generic competition in parts of Europe, and certain U.S. generic makers have settlement agreements allowing future launches.
- 2Government pricing rules, rebates and other limits can reduce the prices or reimbursement Bristol Myers Squibb receives. Medicare price-setting applies to Eliquis and Pomalyst, and Orencia has been selected for a future government price negotiation.
- 3Clinical trials can fail or be delayed, and regulators may not approve new medicines or expanded uses. That could make it harder for the company to replace sales of older medicines as they lose protection from generic competition.
Over Bristol Myers Squibb Co.
Bristol Myers Squibb researches, develops, manufactures and sells prescription medicines around the world. Its medicines treat diseases including cancer, blood disorders, immune conditions, heart disease and schizophrenia. It sells mainly to wholesalers, distributors and pharmacies, and also earns royalties and other revenue through partnerships.
- Hoofdkantoor
- Lawrence Township, New Jersey (Princeton area)
- Opgericht in
- 1887 (predecessor business; incorporated as Bristol-Myers Company in 1933)
- Medewerkers
- Approximately 32,500 (December 31, 2025, high)
- Genoteerd aan
- NYSE
- Einde boekjaar
- December 31
Gebouwd uit de eigen deponeringen van Bristol Myers Squibb Co. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
